Search Results - MacNicholas, R.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Good clinical outcomes following transjugular intrahepatic portosystemic stent‐shunts in Budd–Chiari syndrome

    Good clinical outcomes following transjugular intrahepatic portosystemic stent‐shunts in Budd–Chiari syndrome by Tripathi, D., MacNicholas, R., Kothari, C., Sunderraj, L., Al‐Hilou, H., Rangarajan, B., Chen, F., Mangat, K., Elias, E., Olliff, S.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Hepatitis B related hepatocellular carcinoma. Screening, screening and more screening

    Hepatitis B related hepatocellular carcinoma. Screening, screening and more screening by Sopena-Falco, J, McCormick, A, MacNicholas, R, Houlihan, D, Bourke, M, Feeney, E

    Published in Irish medical journal
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    P942 GOOD CLINICAL OUTCOMES FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNTS (TIPSS) IN BUDD CHIARI SYNDROME: LONG TERM FOLLOW UP IN A SINGLE CENTRE

    P942 GOOD CLINICAL OUTCOMES FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNTS (TIPSS) IN BUDD CHIARI SYNDROME: LONG TERM FOLLOW UP IN A SINGLE CENTRE by Tripathi, D, Macnicholas, R, Kothari, C, Sunderraj, L, Al-Hilou, H, Rangarajan, B, Chen, F, Mangat, K, Elias, E, Olliff, S

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Commentary: TIPSS for Budd–Chiari syndrome – authors' reply

    Commentary: TIPSS for Budd–Chiari syndrome – authors' reply by Tripathi, D., MacNicholas, R., Kothari, C., Sunderraj, L., Al‐Hilou, H., Rangarajan, B., Chen, F., Mangat, K., Elias, E., Olliff, S.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  5. 5
    SAT-457 - Hepatoprotective biomarkers, amphiregulin and soluble Fas, increase during ELAD treatment in alcoholic hepatitis subjects

    SAT-457 - Hepatoprotective biomarkers, amphiregulin and soluble Fas, increase during ELAD treatment in alcoholic hepatitis subjects by Bedard, P., Lapetoda, J., Landeen, L., Al-Khafaji, A., Parikh, A., Duarte-Rojo, A., Borg, B., Mccaughan, G., Stein, L., Teperman, L., Allison, M., Shah, N., Subramanian, R., Malik, R., Brown, R., Macnicholas, R., Habib, S., Asrani, S., Adhami, T.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Hepatoprotective biomarkers, amphiregulin and soluble Fas, increase during ELAD treatment in alcoholic hepatitis subjects

    Hepatoprotective biomarkers, amphiregulin and soluble Fas, increase during ELAD treatment in alcoholic hepatitis subjects by Bedard, P., Lapetoda, J., Landeen, L., Al-Khafaji, A., Parikh, A., Duarte-Rojo, A., Borg, B., Mccaughan, G., Stein, L., Teperman, L., Allison, M., Shah, N., Subramanian, R., Malik, R., Brown, R., Macnicholas, R., Habib, S., Asrani, S., Adhami, T.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: